Today we announced 12-month safety and efficacy data from the ongoing Phase I/II clinical trial of ATSN-101, our investigational #GeneTherapy for GUCY2D-associated #LeberCongenitalAmaurosis (#LCA1). ATSN-101 continues to demonstrate clinically meaningful improvements in vision at the highest dose and is well-tolerated 12 months post-treatment. We are pleased that the 12-month data have been accepted for presentation at the 47th Annual Macula Society Meeting, which will be held February 7-10, 2024, in Palm Springs, CA. These encouraging data and the recent #RMAT designation underscore the potential of our subretinal gene therapy to fill a significant unmet need within the LCA community. Read more: https://lnkd.in/e5rNk-AA
Fantastic news!
Congratulations!
Congratulations!
Performance and Productivity Project Manager
10moAny update on results for ATSN-201 Lighthouse Study? Congrats on positive results with this one.